1
Return

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer

delete2026-06-26
delete0
delete
OA
AI
S
Seonghae Yoon
M
Min-Hee Ryu
S
Seung Tae Kim *
T
Tae-Yong Kim
H
Hye Sook Han
M
Minkyu Jung
J
Jee Hyun Kim
D
Dae Young Zang
K
Keun-Wook Lee
DOI：10.1093/oncolo/oyag245delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
This phase IB/II study assessed safety, pharmacokinetics, and efficacy of alpelisib, a selective PI3Kα inhibitor, plus weekly paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer (GC).

Journal

T
The Oncologist
IF:
0
Papers:
188
Citations:
0

Organization

S
Seoul National University Bundang Hospital
Scholars:
584
Papers: 245
Citations: 5.6K
S
Sungkyunkwan University School of Medicine
Scholars:
1.1K
Papers: 426
Citations: 2
S
Seoul National University Hospital
Scholars:
1.1W
Papers: 9.4K
Citations: 9.3K
H
Hallym University Medical Center
Scholars:
15
Papers: 16
Citations: 248
C
Chungbuk National University Hospital
Scholars:
943
Papers: 733
Citations: 573
Y
Yonsei University
Scholars:
4.7W
Papers: 4.5W
Citations: 5.2W
A
Asan Medical Center
Scholars:
7.7K
Papers: 6.3K
Citations: 8.9K
Cited Papers

Cited Papers

Citing Papers

Citing Papers